Evidence map›Paper›PMID 34160288›Full record

Trial reportAmerican journal of physiology. Regulatory, integrative and comparative physiology2021

Effects of altitude and recombinant human erythropoietin on iron metabolism: a randomized controlled trial.

Andreas Breenfeldt Andersen, Thomas C Bonne, Jacob Bejder, Grace Jung, Tomas Ganz, Elizabeta Nemeth, Niels Vidiendal Olsen, Jesús Rodríguez Huertas, Nikolai Baastrup Nordsborg

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of physiology. Regulatory, integrative and comparative physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Andreas Breenfeldt AndersenDepartment of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-3361-3009
Thomas C BonneDepartment of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-4714-1981
Jacob BejderDepartment of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-9698-9188
Grace JungDepartment of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Tomas GanzDepartment of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Elizabeta NemethDepartment of Medicine and Pathology, Center for Iron Disorders, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Niels Vidiendal OlsenDepartment of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Jesús Rodríguez HuertasDepartment of Physiology, Faculty of Sport Sciences, Institute of Nutrition and Food Technology, Biomedical Research Centre, University of Granada, Armilla, Spain.ORCID 0000-0002-7446-0857
Nikolai Baastrup NordsborgDepartment of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-7077-9265
University of Copenhagen · DKUniversity of California, Los Angeles · USUniversidad de Granada · ES

Funding

Iron physiology and pathology in pregnancyR01HD096863 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2019 to 2023
$2.1M
Erythroferrone and Its Impact on Maternal and Neonatal Iron HomeostasisR21HD098864 · NICHD · CORNELL UNIVERSITY · PI NEMETH, ELIZABETA, O'BRIEN, KIMBERLY O · 2019 to 2020
$445k
NICHD NIH HHS R01 HD096863
6 · The paper itself

Abstract

Current markers of iron deficiency (ID), such as ferritin and hemoglobin, have shortcomings, and hepcidin and erythroferrone (ERFE) could be of clinical relevance in relation to early assessment of ID. Here, we evaluate whether exposure to altitude-induced hypoxia (2,320 m) alone, or in combination with recombinant human erythropoietin (rHuEPO) treatment, affects hepcidin and ERFE levels before alterations in routine ID biomarkers and stress erythropoiesis manifest. Two interventions were completed, each comprising a 4-wk baseline, a 4-wk intervention at either sea level or altitude, and a 4-wk follow-up. Participants (

Indexed as

AltitudeAltitude SicknessBiomarkersDenmarkDouble-Blind MethodEpoetin AlfaErythropoiesisFemaleHematinicsHepcidinsHomeostasisHumansInjections, IntravenousIronMalePeptide HormonesBiomarkersEpoetin AlfaErfe protein, humanHAMP protein, humanHematinicsHepcidinsIronPeptide HormonesRecombinant Proteinsaltitudeantidopingbiomarkererythroferronehepcidin

Identifiers

PMID34160288
PMCPMC8887998
OpenAlexW3175251345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.